期刊文献+

Clinical Observation on the Treatment of Atrial Fibrillation with Amiodarone Combined with Shenmai Injection (参麦注射液) 被引量:3

Clinical Observation on the Treatment of Atrial Fibrillation with Amiodarone Combined with Shenmai Injection (参麦注射液)
原文传递
导出
摘要 Objective: To observe the therapeutic efficacy and safety of amiodarone combined with Shenmai Injection (参麦注射液) on atrial fibrillation. Methods: A total of 351 patients with atrial fibrillation caused by cardiovascular diseases and idiopathic atrial fibrillation were assigned to amiodarone group (control group, 128 cases) and amiodarone combined with Shenmai Injection group (treatment group, 223 cases). The patients in the control group received intravenous injection of 150 mg amiodarone in 10 min, followed by intravenous drip infusion at 1 mg /min and 6 h later at 0.5 mg /min until 48 h or cardioversion. The patients in the treatment group received the same treatment of amiodarone, while in addition, they received an injection of Shenmai Injection of 100 mL simultaneously. Blood pressure, ventricular rate, and cardioversion were observed. Results: The total efficiency rate was 98% (control group) and 99% (treatment group) (P0.05). The mean ventricular rate decreased 23% and 31% in the control group and the treatment group, respectively (P0.05). The mean cardioversion time of the two groups was 570±211 min and 351±123 min, respectively (P0.05). Only mild side effects were observed in both groups. Conclusion: Compared with amiodarone, amiodarone combined with Shenmai Injection takes effect more quickly with low side effects on the treatment of atrial fibrillation. Objective: To observe the therapeutic efficacy and safety of amiodarone combined with Shenmai Injection (参麦注射液) on atrial fibrillation. Methods: A total of 351 patients with atrial fibrillation caused by cardiovascular diseases and idiopathic atrial fibrillation were assigned to amiodarone group (control group, 128 cases) and amiodarone combined with Shenmai Injection group (treatment group, 223 cases). The patients in the control group received intravenous injection of 150 mg amiodarone in 10 min, followed by intravenous drip infusion at 1 mg /min and 6 h later at 0.5 mg /min until 48 h or cardioversion. The patients in the treatment group received the same treatment of amiodarone, while in addition, they received an injection of Shenmai Injection of 100 mL simultaneously. Blood pressure, ventricular rate, and cardioversion were observed. Results: The total efficiency rate was 98% (control group) and 99% (treatment group) (P0.05). The mean ventricular rate decreased 23% and 31% in the control group and the treatment group, respectively (P0.05). The mean cardioversion time of the two groups was 570±211 min and 351±123 min, respectively (P0.05). Only mild side effects were observed in both groups. Conclusion: Compared with amiodarone, amiodarone combined with Shenmai Injection takes effect more quickly with low side effects on the treatment of atrial fibrillation.
出处 《Chinese Journal of Integrative Medicine》 SCIE CAS 2010年第5期453-456,共4页 中国结合医学杂志(英文版)
关键词 atrial fibrillation AMIODARONE Shenmai Injection atrial fibrillation amiodarone Shenmai Injection
  • 相关文献

参考文献15

  • 1Vijayalakshmi K, Whittaker V J, Sutton A, Campbell P, Wright RA, Hall JA, et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J 2006;52:863-866.
  • 2Saksena S, Madan N. Hybrid therapy of atrial fibrillation: algorithms and outcome. J Interv Cardid Electrophysiol 2003;9:235-247.
  • 3ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006:114:257-354.
  • 4Chen X. Clinical arrhythmology-electrophysiology and treatment. Beijing: People's Medical Publishing House; 2000:780-789.
  • 5Cao K J, Chen ML. Strengthen the comprehensive therapy of atrial fibrillation. Chin J Cardio12006;34:766-768.
  • 6Gotsman I, Zwas D, Planer D, Azaz-Livshits T, Admon D, Lotan C, et al. Clinical outcome of patients with heart failure and preserved left ventricular function. Am J Med 2008:121:997-1001.
  • 7Meng F, Yoshikawa, Baba A, Moritani K, Suzuki M, Satoh T, et al. Beta-blockers are effective in congestive heart failure patients with artrial fibrillation. J Card Fail 2003; 9:398-403.
  • 8Tuseth V, Jaatun H J, Dickstein K. Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment. Heart 2005;91:964-965.
  • 9Cybulski J, Kulakowski P, Budaj A, Danielewicz H, Maciejewicz J, Kawka-Urbanek T, et al. Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation. Clin Cardiol 2003;26:329-335.
  • 10Li YL. Clinical observation on the preventive effect of Shenmai Injection on arrhythmia induced by aconitine toxication. Acad Periodical Changchun Coil Tradit Chin Med (Chin) 2000;16(1):16.

同被引文献26

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部